Screening of Antiurolithiatic Drugs

Screening of Antiurolithiatic Drugs

1. Definition, scope & rationale

• Antiurolithiatic (antilithiatic / anti-calculi) drug screening = the experimental (in-vitro + in-vivo) evaluation of a candidate compound's ability to prevent, dissolve, or reduce the formation of urinary calculi and the associated renal crystal deposition, hyperoxaluria and renal injury. This is an experimental-pharmacology / drug-screening topic (RGUHS/NMC MD Pharmacology practical curriculum), NOT clinical management of urolithiasis.
• Urolithiasis is a multifactorial disorder in which supersaturated urine permits crystal nucleation → growth → aggregation → retention → calculus formation; ~75–80% of human stones are calcium oxalate (CaOx), the rest being calcium phosphate, struvite (magnesium ammonium phosphate), uric acid and cystine. Screening models are chosen to mimic the dominant CaOx pathway or, for infection/foreign-body stones, the struvite pathway. [PMID 16850024]
• Why a screening battery is needed: no single assay captures all of nucleation-inhibition, crystal-growth-inhibition, aggregation-inhibition, hyperoxaluria-lowering and renal-protective effects. A validated program therefore couples in-vitro crystallisation assays (cheap, high-throughput, mechanism-defining) with an in-vivo lithogenic model (integrates whole-animal handling of the stone-forming ions, renal crystal retention, and toxicity). [PMID 26558080]
• Reference/standard comparators anchor every screen: Cystone® (a polyherbal Ayurvedic formulation) is the near-universal positive control in the Indian antiurolithiatic literature; potassium citrate and thiazide diuretics are the mechanism-defined pharmacological standards (citrate as a physiological CaOx crystallisation inhibitor; thiazides as hypocalciuric agents). [PMID 26187510] (G&G 14e Ch.29 grounds the thiazide/citrate mechanisms)
• Regulatory-methodology backdrop: Vogel Part III supplies the generic urinary-tract assay infrastructure that every antiurolithiatic protocol re-uses — metabolic-cage timed-urine collection, renal-function/clearance measurement, and renal histopathology scoring (Vogel V1 Part III, pp.835–930). Antiurolithiatic screening is essentially this infrastructure applied to a lithogenic challenge. (Vogel V1 Part III, pp.835–930)